ArticleJournal of medicinal chemistry2025
Synthesis and Biological Evaluation of MEK/mTOR Multifunctional Inhibitors as Novel Anticancer Agents.
Marcian E Van Dort, Lucas McDonald, Youngsoon Jang, Kevin Heist, Christopher A Bonham, Kamryn Abraskin, Thomas L Chenevert, Brian D Ross
Abstract read
In one paragraphArticle in Journal of medicinal chemistry, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registryThe trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
3 · Its place in the literatureWho cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
4 · The recordCorrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what moneyAuthors and funding
8 authors.
Marcian E Van DortCenter for Molecular Imaging, The University of Michigan Medical School, Ann Arbor, Michigan 48109, United States.ORCID 0000-0002-4206-6230 Lucas McDonaldCenter for Molecular Imaging, The University of Michigan Medical School, Ann Arbor, Michigan 48109, United States.
Youngsoon JangCenter for Molecular Imaging, The University of Michigan Medical School, Ann Arbor, Michigan 48109, United States.
Kevin HeistCenter for Molecular Imaging, The University of Michigan Medical School, Ann Arbor, Michigan 48109, United States.ORCID 0000-0001-5161-0608 Christopher A BonhamCenter for Molecular Imaging, The University of Michigan Medical School, Ann Arbor, Michigan 48109, United States.
Kamryn AbraskinCenter for Molecular Imaging, The University of Michigan Medical School, Ann Arbor, Michigan 48109, United States.ORCID 0009-0007-1390-6994 Thomas L ChenevertCenter for Molecular Imaging, The University of Michigan Medical School, Ann Arbor, Michigan 48109, United States.
Brian D RossCenter for Molecular Imaging, The University of Michigan Medical School, Ann Arbor, Michigan 48109, United States.ORCID 0000-0003-2695-9140 Funding
XenograftP30CA046592 · NCI · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI Alexey I Nesvizhskii · 1988 to 2026
$178.2MImaging Disease Heterogeneity and Response to Therapy in MyelofibrosisR01CA238023 · NCI · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI LUKER, GARY D, ROSS, BRIAN D. · 2019 to 2023
$3.1MImage Biomarker Development for TreatmentEfficacy of Prostate Cancer to the BoneR01CA136892 · NCI · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI ROSS, BRIAN D. · 2009 to 2012
$2.1MDevelopment of quantitative bone marrow magnetic resonance imaging biomarkers to assess efficacy of novel molecularly targeted agents for myelofibrosisR01CA297995 · NCI · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI Brian D. Ross · 2025 to 2026
$1.3MNCI NIH HHS P30 CA046592NCI NIH HHS R01 CA136892NCI NIH HHS R01 CA238023NCI NIH HHS R01 CA297995
6 · The paper itselfAbstract
The mitogen-activated protein kinase (MAPK) and mechanistic target of rapamycin (mTOR) signaling nodes play a crucial role in many human cancers. Due to the molecular reciprocity between MAPK and mTOR signaling nodes, development of compounds with multikinase targeting was explored. A series of mTOR inhibitor analogs of AZD8055 and AZD2014 were designed to allow for covalent linking to a potent MAPK kinase (MEK) inhibitor to produce a single, bivalent chemical entity. Dual-acting agents (i.e., compound LP-65) were synthesized displaying high in vitro inhibition of both MEK (IC
Indexed as
Antineoplastic AgentsMitogen-Activated Protein Kinase KinasesMTOR InhibitorsProtein Kinase InhibitorsTOR Serine-Threonine KinasesAnimalsCell Line, TumorCell MovementCell ProliferationHumansMiceStructure-Activity RelationshipAntineoplastic AgentsMitogen-Activated Protein Kinase KinasesMTOR InhibitorsMTOR protein, humanProtein Kinase InhibitorsTOR Serine-Threonine Kinases
Identifiers
PMID40375738
PMCPMC12435495
What OpenQuestion holds
Textmetadata
LicenceTDM
Read underepoch 390